To provide the information your oncologist is not telling you or doesn't have the time to!
Unleash the power of your body’s immune system in the fight against cancer with our “Immunotherapy” subcategory. Delve into the realm of groundbreaking treatments that empower your immune system to recognize and combat cancer cells. Explore the latest advances in immunotherapy, from checkpoint inhibitors to CAR-T cell therapies, and learn how they are revolutionizing the landscape of cancer treatment. Join us on a journey to understand how harnessing your body’s natural defenses is paving the way for more targeted and effective therapies in the fight against cancer.
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), poses significant treatment challenges due to its high recurrence rate and aggressive nature. Traditionally, neoadjuvant chemotherapy followed by surgery (radical cystectomy) has been the standard of care for cisplatin-eligible patients. However, researchers have been exploring ways to improve outcomes by incorporating immunotherapy into treatment. A recent phase 3 …
Colon cancer treatments have long relied on surgery, chemotherapy, and radiation. However, recent breakthroughs in immunotherapy, particularly for mismatch repair–deficient (dMMR) tumors, are reshaping how certain high-risk cancers are treated. A recent study published in The New England Journal of Medicine provides encouraging data on the effectiveness of neoadjuvant immunotherapy for patients with locally advanced dMMR colon …
Immunotherapy has made significant strides in cancer treatment, but microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has long posed a challenge due to its resistance to immune-based therapies. However, promising results from a recent phase 2/3 trial have shown that the individualized neoantigen-directed immunotherapy, GRANITE, may change the outlook for patients with MSS mCRC. This innovative therapy, combined …
Small-cell lung cancer (SCLC) is a notoriously aggressive form of lung cancer, making up about 15% of all lung cancer cases. While treatments have made strides in extensive-stage SCLC, limited-stage SCLC has seen few advancements in decades—until now. A new clinical trial published in the New England Journal of Medicine has revealed promising results with the use …
A Promising New Treatment for Metastatic Breast Cancer: Exploring Bria-IMT™ and Its Impact When battling metastatic breast cancer, finding effective treatment options can feel like an uphill battle, especially when cancer has spread to other areas, like the brain. But new hope is on the horizon. A groundbreaking therapy called Bria-IMT™ is showing promising results in clinical …
October is Breast Cancer Awareness Month, a time dedicated to spreading knowledge, supporting research, and empowering patients and healthcare providers alike. Throughout the month, we’ll explore various critical aspects of breast cancer care. In this post, we focus on the current role of immunotherapy in treatment and encourage both patients and providers to consider clinical …
When I meet new patients diagnosed with Stage IV metastatic melanoma, I often mention the name Jimmy Carter. It’s a name most people recognize, and his survival story is nothing short of remarkable—especially considering he will soon celebrate his 100th birthday. Like many of my patients, Carter was diagnosed with Stage IV melanoma, with metastatic …
The American Society of Clinical Oncology (ASCO) 2024 conference was a remarkable event, bringing together leading minds in oncology to discuss the latest breakthroughs and research in cancer treatment. This year’s conference was particularly notable for the innovative approaches presented in the treatment of metastatic melanoma, a challenging and aggressive form of skin cancer. In …
The medical community continues to explore groundbreaking treatments in the fight against cancer, with CAR-T therapy standing out for its innovative approach. This treatment, involving the genetic modification of a patient’s T cells to target cancer cells, has provided new avenues for those battling certain blood cancers. Here, we delve into the essence of CAR-T …
Last week, we heard the tremendous news regarding the FDA approval of Lifileucel for metastatic melanoma refractory to prior immunotherapy checkpoint inhibitor therapy. In this article, let’s focus on an uncommon melanoma subtype in the general population that we routinely see in practice. In the realm of oncology, the fight against cancer continually evolves, marked …